ESR1 and breast cancer: In humans, upon acquisition of additional mutations, theRUNX1/TP53-mutant or RUNX1/RB1-mutantER+ premalignant luminal cells may progress to ER+luminal breast cancer, upon acquisition of additional oncogenic events (Figure 8B).